Decoglurant (INN) (code name RG1578, RO4995819) is a negative allosteric modulator of the mGlu2 and mGlu3 receptors which was under development by Roche for the adjunctive treatment of major depressive disorder. Decoglurant progressed as far as phase II clinical trials but was ultimately discontinued from further development due to disappointing efficacy results.

Property Value
dbo:abstract
  • Decoglurant (INN) (code name RG1578, RO4995819) is a negative allosteric modulator of the mGlu2 and mGlu3 receptors which was under development by Roche for the adjunctive treatment of major depressive disorder. Decoglurant progressed as far as phase II clinical trials but was ultimately discontinued from further development due to disappointing efficacy results. (en)
dbo:thumbnail
dbo:wikiPageEditLink
dbo:wikiPageExternalLink
dbo:wikiPageExtracted
  • 2019-09-28 20:14:43Z (xsd:date)
dbo:wikiPageHistoryLink
dbo:wikiPageID
  • 43450364 (xsd:integer)
dbo:wikiPageLength
  • 3476 (xsd:integer)
dbo:wikiPageModified
  • 2019-09-28 20:12:02Z (xsd:date)
dbo:wikiPageOutDegree
  • 17 (xsd:integer)
dbo:wikiPageRevisionID
  • 918465440 (xsd:integer)
dbo:wikiPageRevisionLink
dbp:wikiPageUsesTemplate
dct:subject
rdfs:comment
  • Decoglurant (INN) (code name RG1578, RO4995819) is a negative allosteric modulator of the mGlu2 and mGlu3 receptors which was under development by Roche for the adjunctive treatment of major depressive disorder. Decoglurant progressed as far as phase II clinical trials but was ultimately discontinued from further development due to disappointing efficacy results. (en)
rdfs:label
  • Decoglurant (en)
owl:sameAs
foaf:depiction
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is foaf:primaryTopic of